Form 8-K BIOTIME INC For: Sep 25
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall Street futures fall as oil, Treasury yields rise on Iran tensions
- Oil prices fall after hitting over one-month high; traders weigh supply risks
- Dell again lifts annual forecasts as AI demand powers record results
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- Berkshire’s Abel says data centers are energy opportunity
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- S&P Global shares rise on report of possible CapIQ spinoff
BioTime (BTX) Announces Receipt of FDA Fast-Track Designation for OpRegen
September 28, 2015 8:03 AM EDTBioTime (NYSE: BTX)and its subsidiary Cell Cure Neurosciences Ltd. (Cell Cure) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for OpRegen®, a cell-based therapeutic product consisting of retinal pigment epithelial (RPE) cells designed to block the progression of the severe dry-form of age-related macular degeneration (AMD), a leading cause of blindness in an aging population.
Under an Investigational New Drug Application (IND) for Retinal Pigment Epithelium (RPE) Cells derived from Allogenic Human Embryonic... More
